Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities
August 6, 2015 4:00 PM EDTAdvanced Pipeline of Seven Investigational Clinical Programs and Presented Positive Clinical Results for Three: Patisiran for Familial Amyloidotic Polyneuropathy (FAP), ALN-AT3 for Hemophilia, and ALN-CC5 for Complement-Mediated Diseases
In Addition to Upcoming Presentation of ALN-PCSsc Clinical Results, Announces New Plan to Present Initial Clinical Data for ALN-AS1 Porphyria Program at Medical Meeting in September and Provides Update on Revusiran Phase 2 Open-Label Extension Study
Maintained Strong Balance Sheet with $1.40 Billion in Cash and Remains On Track to End 2015 with Greater than $1.2 Billion in Cash
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
